In addition, notwithstanding the rushing impact of biotechnology drugs, Big Pharma’s investment in these molecules is constantly on a positive trend, with large numbers of approved new molecular entities [NME] each year [ 17 ].
← all excerpts
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams.
1
—
—